UroGen Pharma Ltd — Cash Flow (NASDAQ:URGN) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities -105.89 M-84.89 M-87.56 M-76.38 M-96.77 M -137.74 M Cash from investing activities 93.24 M4.07 M1.06 M-953 K-20.61 M 94.46 M Cash from financing activities 16.53 M72.32 M97.13 M116.93 M194.62 M 8.67 M Free cash flow -107.1 M-85.64 M-87.81 M-76.57 M-97.06 M -138.13 M

Haberler

UroGen Pharma CMO Schoenberg sells $145k in shares

enGene Holdings: A Potential Oncology Entrant (NASDAQ:ENGN)

2025 Performance Review And Future Strategy

Urogen Pharma Ltd stock hits 52-week high at 25.2 USD

UroGen Pharma at Guggenheim Conference: Strategic Insights into UGN-102 Launch

Urogen Pharma stock hits 52-week high at 23.66 USD

UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript

UroGen Pharma stock jumps after positive Phase 3 trial results

UroGen Pharma stock price target raised to $30 from $25 at D. Boral Capital

Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates

UroGen Pharma earnings missed, revenue fell short of estimates

UroGen reports 77.8% response rate in bladder cancer drug trial